◎ Sugi Atlas

Atlas / Disease / Endocarditis

Endocarditis

disease
On this page

Also known as endocarditis (disease)endocardium inflammationinflammation of endocardium

Summary

Endocarditis (MONDO:0005025) is a disease with 5 GWAS associations across 13 studies and 49 clinical trials. Top therapeutic interventions include cephalexin anhydrous, clindamycin, and doxycycline anhydrous. A subtype of endocardium disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • GWAS associations: 5
  • Clinical trials: 49

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameendocarditis
Mondo IDMONDO:0005025
EFOEFO:0000465
MeSHD004696
DOIDDOID:10314
NCITC34582
SNOMED CT56819008
UMLSC0014118
MedGen4940
Is cancer (heuristic)no

Also known as: endocarditis · endocarditis (disease) · endocardium inflammation · inflammation of endocardium

Data availability: 5 GWAS associations (13 studies) · 1 HPO phenotype.

Disease family

An umbrella term covering 3 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › heart disorder › endocardium disorder › endocarditis

Related subtypes (2): endocardial fibroelastosis, neoplasm of endocardium

Subtypes (3): infective endocarditis, marantic endocarditis, Libman-Sacks endocarditis

Genetics & variants

GWAS landscape

5 GWAS associations across 13 studies. Top hits map to 3 distinct genes (as reported by GWAS).

Top associations by p-value

rsIDp-valueGeneRisk alleleOdds ratio
rs5581888472e-12DUOXA1G2.5
rs5587191691e-11EIF2AK1C2.56
rs8684598302e-11TBC1D8A2.13
rs1906343602e-11LINC02046 - RPL38P1C1.3
rs1903709494e-10FER1L6-AS2 - RNU6-756P?

Top studies (by case count)

StudyLead authorYearCasesControlsTitle
GCST90477896Verma A20243,358443,352Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90473561UK Biobank Whole-Genome Sequencing Consortium20251,129457,311Whole-genome sequencing of 490,640 UK Biobank participants.
GCST90281158Hamilton FW20231,080485,404Therapeutic potential of IL6R blockade for the treatment of sepsis and sepsis-related death: A Mendelian randomisation study.
GCST90477895Verma A2024772119,962Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90480146Verma A2024772119,962Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90436093Zhou W2018686405,779Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies.
GCST90473556UK Biobank Whole-Genome Sequencing Consortium2025644457,796Whole-genome sequencing of 490,640 UK Biobank participants.
GCST90079997Backman JD2021572387,181Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90083983Backman JD2021572387,181Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90481986Verma A202433558,989Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

TierVariants
Tier 1: coding0
Tier 2: splice/UTR0
Tier 3: regulatory0
Tier 4: intronic/intergenic5

MAF distribution

BucketVariants
common (>=0.05)0
low_freq (0.01-0.05)0
rare (<0.01)4
unknown1

Functional consequences

ConsequenceCount
intron_variant5

Top variants

rsIDChrPosAllelesMAFConsequenceGenep-valueTier
rs5581888471545127234G>A0intron_variantDUOXA12e-12Tier 4: intronic/intergenic
rs55871916976046501C>A,T0.001intron_variantEIF2AK11e-11Tier 4: intronic/intergenic
rs8684598302101032963A>G,T0intron_variantTBC1D82e-11Tier 4: intronic/intergenic
rs1906343603148450952C>T0.007intron_variantLINC02046 - RPL38P12e-11Tier 4: intronic/intergenic
rs1903709498124232491T>Gintron_variantFER1L6-AS2 - RNU6-756P4e-10Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

2 approved, 2 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

DrugDevelopment status
DaptomycinApproved (phase 4)
VancomycinApproved (phase 4)
AmoxicillinPhase 3 (in late-stage trials)
RifampinPhase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Ceftriaxone, Gallium Citrate, Oxygen.

Clinical trials & evidence

Clinical trials

Clinical trials: 49.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified37
PHASE410
PHASE1/PHASE21
PHASE21

Top trials by phase / activity

NCTPhaseStatusTitle
NCT05144399PHASE4RECRUITINGAccelerated Treatment of Endocarditis
NCT06422221PHASE4NOT_YET_RECRUITINGAn Oral Doxycycline Regimen to Prevent Bacteremia Following Dental Procedures
NCT00709358PHASE4COMPLETEDDiagnosis of Septicaemia by Detection of Microbial DNA in Blood in Severe Infections
NCT00750373PHASE4COMPLETEDEarly Surgery Versus Conventional Treatment in Infective Endocarditis
NCT01375257PHASE4COMPLETEDPartial Oral Treatment of Endocarditis
NCT01734694PHASE4TERMINATEDSafety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients
NCT02443064PHASE4UNKNOWNPharmacokinetics/ Pharmacodynamics (PK/PD) Study of Vancomycin
NCT02783404PHASE4TERMINATEDAn Oral Amoxicillin-Clavulanate Regimen to Prevent Bacteremia Following Dental Procedures
NCT03112356PHASE4UNKNOWNThe Value of 99mTc-Leukoscan® Scintigraphy in the Diagnosis of Infectious Endocarditis on Surgical Materials
NCT05156437PHASE4TERMINATEDPostoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL)
NCT02459613PHASE1/PHASE2TERMINATEDAssessment of Radiolabeled rhAnnexin V-128 in Infective Endocarditis
NCT03148756PHASE2TERMINATEDEfficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Infective Endocarditis
NCT03718052Not specifiedACTIVE_NOT_RECRUITINGEarly Valve Surgery Versus Conventional Treatment in Infective Endocarditis Patients With High Risk of Embolism
NCT03892174Not specifiedRECRUITINGCytokine REmoval in CRitically Ill PAtients Requiring Surgical Therapy for Infective Endocarditis (RECReATE)
NCT05139589Not specifiedRECRUITINGThe ENDOCARDITIS AUMC Data Collection
NCT05146180Not specifiedRECRUITINGInterest of Parametric Positron Emission Imaging in the Diagnosis of Infections on Cardiac Valve Prosthesis
NCT05146336Not specifiedRECRUITINGCytOSorb TreatMent Of Critically Ill PatientS Registry
NCT05547607Not specifiedRECRUITINGClinical and Diagnostic Features of Endocarditis
NCT05613933Not specifiedNOT_YET_RECRUITINGEffectiveness of Antibiotic Prophylaxis of Infective Endocarditis for Invasive Dental Procedures in Patients With Prosthetic Heart Valves and/or History of Infective Endocarditis
NCT06403839Not specifiedRECRUITINGImpact of Preoperative Dental Screening in Reducing Infective Endocarditis Risk in Surgical Valve Replacement Patients
NCT06434012Not specifiedRECRUITINGBarts Endocarditis Research Registry
NCT00166023Not specifiedCOMPLETEDOutcomes Following Medical or Surgical Management of Endocarditis
NCT00548002Not specifiedCOMPLETEDCombination Therapy With Fluoroquinolone in Staphylococcus Aureus Bacteremia
NCT00579761Not specifiedWITHDRAWNRetrospective Review of Management of Infective Endocarditis
NCT00590889Not specifiedTERMINATEDArtificial Valve Endocarditis Reduction Trial
NCT00995384Not specifiedTERMINATEDCardiac Computed Tomography (CT) Scan Compared to Transesophageal Echocardiogram (TEE) in Endocarditis
NCT01301638Not specifiedUNKNOWNRetrospective Evaluation of Safety and Efficacy of Daptomycin Used in Patients With Serious Gram-positive Infections
NCT01431326Not specifiedCOMPLETEDPharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
NCT02026895Not specifiedCOMPLETEDVirulence of Staphylococcus Lugdunensis in Severe Infections
NCT02251262Not specifiedCOMPLETEDDiagnostic Accuracy of 18FDG-PET-CT for Pacing or Defibrillation Lead Infection
NCT02759978Not specifiedUNKNOWNIndividualized Diagnosis of Endocarditis and Its Therapy With a Focus on Infected Prosthetic materiAL
NCT03231449Not specifiedUNKNOWNA Survey of Hospitalizations in Cardiology Units in Sub-Saharan Africa
NCT03377465Not specifiedCOMPLETEDBiomarkers, Hemodynamic and Echocardiographic Predictors of Ischemic Strokes and Their Influence on the Course and Prognosis
NCT03411499Not specifiedTERMINATEDStroke-free Survival Comparison Between Early Surgery and Conventional Therapy in Left Infective Endocarditis
NCT03429153Not specifiedUNKNOWNManagement of Infectious Endocarditis as Part of a Multidisciplinary Consensus Meeting
NCT03690076Not specifiedUNKNOWNHuman Cardiac Mitochondria in Acute Endocarditis and Obesity
NCT03695861Not specifiedCOMPLETEDContribution of 18F-FDG PET-CT in the Diagnosis and the Detection of Peripheral Emboli of Infectious Endocarditis on Native Valves
NCT04068337Not specifiedCOMPLETEDFreestyle Prosthesis for Aortic Root-replacement With and Without Hemiarch Replacement
NCT04309591Not specifiedCOMPLETEDCytosorb Therapy in Cardiac Surgery
NCT04387513Not specifiedCOMPLETEDImpact of Early Cardiac Surgery in Severe Left Endocarditis With Neurological Complications: a Retrospective Study

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
CEPHALEXIN ANHYDROUS43
CLINDAMYCIN43
DOXYCYCLINE ANHYDROUS43
VANCOMYCIN43
CEFTAROLINE FOSAMIL42
DAPTOMYCIN42
LEVOFLOXACIN ANHYDROUS42
LINEZOLID42
AMOXICILLIN41
AMPICILLIN41
CEFEPIME41
CEFTRIAXONE41
CLAVULANIC ACID41
COPPER OXODOTREOTIDE CU-6441
DALBAVANCIN41
DICLOXACILLIN41
OFLOXACIN41
OXACILLIN41
RIFAMPIN41
TROVAFLOXACIN41
CEFTAROLINE32
CHEMBL429943603
CHEMBL164972202
CHEMBL428678402
CHEMBL474444402
CHEMBL38826601
CHEMBL477823901
CHEMBL478539201
CHEMBL617470501

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 21

This page pulls from 21 datasets indexed by BioBTree:

chembl_moleculecivic_evidenceclinical_trialsclinvardbsnpdoidefogenccgwasgwas_studyhgncmedgenmeshmimmondomondochildmondoparentncitorphanetsctidumls